• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib.

作者信息

Yamamura Yuriko, Matsumoto Yoshinori, Asano Yosuke, Katayama Yu, Hayashi Keigo, Ohashi Keiji, Morishita Michiko, Watanabe Haruki, Takano-Narazaki Mariko, Sada Ken-Ei, Wada Jun

机构信息

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

出版信息

Rheumatol Adv Pract. 2019 Dec 23;4(1):rkz050. doi: 10.1093/rap/rkz050. eCollection 2020.

DOI:10.1093/rap/rkz050
PMID:32016168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6991178/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0eb/6991178/fa9eef1f72e1/rkz050f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0eb/6991178/fa9eef1f72e1/rkz050f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0eb/6991178/fa9eef1f72e1/rkz050f1.jpg

相似文献

1
Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib.对口服Janus激酶抑制剂托法替布有反应的难治性大动脉炎
Rheumatol Adv Pract. 2019 Dec 23;4(1):rkz050. doi: 10.1093/rap/rkz050. eCollection 2020.
2
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.托法替尼，一种口服 Janus 激酶抑制剂，用于治疗慢性斑块型银屑病：来自 2 项随机 III 期研究和 1 项开放标签长期扩展研究的长期疗效和安全性结果。
J Am Acad Dermatol. 2016 May;74(5):841-50. doi: 10.1016/j.jaad.2016.01.013. Epub 2016 Feb 19.
3
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.托法替布，一种口服的 Janus 激酶抑制剂，用于治疗拉丁美洲类风湿关节炎患者：3 期和长期扩展研究的汇总疗效及安全性分析
Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15.
4
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.在健康志愿者中单次口服托法替尼（一种 Janus 激酶抑制剂）的安全性、耐受性和药代动力学。
Clin Pharmacol Drug Dev. 2015 Mar;4(2):83-8. doi: 10.1002/cpdd.171. Epub 2014 Dec 5.
5
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.口服托法替布：其在皮肤科作用的当代评估
Indian Dermatol Online J. 2019 Aug 28;10(5):503-518. doi: 10.4103/idoj.IDOJ_474_18. eCollection 2019 Sep-Oct.
6
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.枸橼酸托法替尼治疗难治性特应性皮炎的疗效观察。
J Am Acad Dermatol. 2015 Sep;73(3):395-9. doi: 10.1016/j.jaad.2015.06.045. Epub 2015 Jul 17.
7
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.在应激条件下，口服Janus激酶抑制剂托法替布而非奥克拉替尼会诱发攻击行为。
Eur J Pharmacol. 2015 Oct 5;764:278-282. doi: 10.1016/j.ejphar.2015.06.060. Epub 2015 Jul 9.
8
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.托法替布：首个用于治疗类风湿关节炎的 Janus 激酶（JAK）抑制剂。
Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790.
9
Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.口服托法替尼与其他常规疗法治疗难治性全秃和普秃的疗效比较：一项回顾性研究。
Acta Derm Venereol. 2019 Jan 1;99(1):41-46. doi: 10.2340/00015555-3057.
10
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.难治性皮肤性皮肌炎的治疗：托法替尼的 Janus 激酶抑制作用的潜在作用。
Rheumatology (Oxford). 2019 Jun 1;58(6):1011-1015. doi: 10.1093/rheumatology/key366.

引用本文的文献

1
Successful Use of Tofacitinib in Refractory Takayasu Arteritis: A Case Series.托法替布在难治性大动脉炎中的成功应用：病例系列
Mediterr J Rheumatol. 2023 Jul 31;34(3):356-362. doi: 10.31138/mjr.230929.su. eCollection 2023 Sep.
2
Advances in Takayasu arteritis: An Asia Pacific perspective.高安动脉炎的进展：亚太地区视角
Front Med (Lausanne). 2022 Aug 15;9:952972. doi: 10.3389/fmed.2022.952972. eCollection 2022.
3
Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

本文引用的文献

1
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.JAK-STAT 信号抑制在大中血管血管炎中的致病性免疫反应。
Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.
2
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).托珠单抗治疗难治性大动脉炎的疗效和安全性：来自日本一项随机、双盲、安慰剂对照、3 期临床试验（TAKT 研究）的结果。
Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30.
3
风湿性疾病背景下T大颗粒淋巴细胞白血病（T-LGLL）的发病机制与治疗
Front Oncol. 2022 Jun 7;12:854499. doi: 10.3389/fonc.2022.854499. eCollection 2022.
4
An Update on Childhood-Onset Takayasu Arteritis.儿童期发病的大动脉炎最新进展
Front Pediatr. 2022 Apr 13;10:872313. doi: 10.3389/fped.2022.872313. eCollection 2022.
5
A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.对Janus激酶抑制剂治疗大血管血管炎的临床和临床前证据的系统评价。
Clin Rheumatol. 2022 Jan;41(1):33-44. doi: 10.1007/s10067-021-05973-4. Epub 2021 Nov 3.
6
Wind of Change in the Treatment of Childhood-Onset Takayasu Arteritis: a Systematic Review.儿童发病型大动脉炎治疗的变革之风：系统评价。
Curr Rheumatol Rep. 2021 Jul 3;23(8):68. doi: 10.1007/s11926-021-01032-8.
7
Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future.Janus激酶/信号转导和转录激活因子通路在血管炎发病机制中的作用：未来可能的治疗靶点
Front Pharmacol. 2021 Mar 29;12:635663. doi: 10.3389/fphar.2021.635663. eCollection 2021.
8
Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.降低大血管血管炎长期糖皮质激素治疗的毒性。
Curr Rheumatol Rep. 2020 Oct 12;22(12):85. doi: 10.1007/s11926-020-00961-0.
9
Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.巨细胞动脉炎和 Takayasu 动脉炎的治疗——现状与未来。
Curr Rheumatol Rep. 2020 Oct 12;22(12):84. doi: 10.1007/s11926-020-00964-x.
10
Tofacitinib in patients with refractory Takayasu's arteritis.托法替布用于难治性大动脉炎患者。
Rheumatology (Oxford). 2020 Nov 1;59(11):e95-e98. doi: 10.1093/rheumatology/keaa281.
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
托法替布（CP-690,550）联合甲氨蝶呤治疗甲氨蝶呤应答不足的类风湿关节炎的 II 期研究。
Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150-8. doi: 10.1002/acr.20494.
4
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.JAK1/JAK3 抑制剂 CP-690,550 在大鼠佐剂性关节炎中介导的抗炎活性和中性粒细胞减少作用。
J Inflamm (Lond). 2010 Aug 11;7:41. doi: 10.1186/1476-9255-7-41.
5
Medium- and large-vessel vasculitis.中、大血管血管炎。
N Engl J Med. 2003 Jul 10;349(2):160-9. doi: 10.1056/NEJMra022694.
6
Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors.120例日本高安氏病患者的长期预后。相关预后因素的临床与统计学分析。
Circulation. 1994 Oct;90(4):1855-60. doi: 10.1161/01.cir.90.4.1855.